Precision Medicine MCP Platform

Dedicated to PatientOne -- a dear friend who passed from High-Grade Serous Ovarian Carcinoma in 2025.

This platform automates multi-modal data processing for clinical decision support — all results require clinician review before any clinical action.

The Problem

A patient can spend months moving between referrals, imaging, repeat evaluations, and denials without reaching a decision. Much of that motion starts at the workup — the test that would have settled the question was never ordered, or the finding that would have opened a door was never generated.

Standard oncology panels (BRCA1/2, HRD, tumor genomic) surface no immunotherapy or investigational hypotheses. Standard lipid panels and population genetic screens miss the tests most likely to change preventive management. Integrating genomics, spatial transcriptomics, imaging, and clinical data by hand is clinically impractical — the platform automates it.

What This Changes for the Patient

This platform does not triage patients or route referrals. It makes the analysis behind a decision complete on the first pass, instead of spread across a sequence of visits.

Fewer tests is also a result. A CAC score of 0 would support deferring statin therapy for PAT003. The same analysis that adds a test can remove one — the goal is the decision, not the volume of workup.

Scope of the claim. These are three synthetic patients analyzed end-to-end, not clinical outcomes. Time and cost figures are modeled and pending clinical validation. The platform's contribution is to the quality and completeness of the decision, not to the referral pathway around it.

The Results

The platform surfaces clinically actionable findings that standard workup cannot reach — 6 investigational hypotheses across 2 cancer types plus 3 preventive health evidence gaps, validated across three independent use cases:

... View full README on GitHub